The COVID-19 impact on severe uncontrolled asthma costs and biologic use.

IF 2.6 3区 医学 Q2 ALLERGY Allergy and asthma proceedings Pub Date : 2023-09-01 DOI:10.2500/aap.2023.44.230045
Najm S Khan, Elizabeth Rubin, Bernard McKenna, Bernard L Palowitch, Frank Sonnenberg, Judith Argon, Reynold A Panettieri
{"title":"The COVID-19 impact on severe uncontrolled asthma costs and biologic use.","authors":"Najm S Khan,&nbsp;Elizabeth Rubin,&nbsp;Bernard McKenna,&nbsp;Bernard L Palowitch,&nbsp;Frank Sonnenberg,&nbsp;Judith Argon,&nbsp;Reynold A Panettieri","doi":"10.2500/aap.2023.44.230045","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Patients with severe uncontrolled asthma (SUA) overwhelmingly contribute to the economic burden of asthma and may require biologic therapy. However, the impact of the CoronaVirus Disease of 2019 (COVID-19) on asthma costs and biologic use has yet to be evaluated. <b>Objective:</b> The objective was to test the hypothesis that SUA costs and biologic use decreased during the pandemic. <b>Methods:</b> We analyzed medical costs and biologic use in patients with SUV from January 2017 to December 2021, by using claims data from a large managed care organization and electronic health record data from Robert Wood Johnson Barnabas Health, according to provider specialty. <b>Results:</b> Of the 3817 managed care organization enrollees within Robert Wood Johnson Barnabas Health with a primary diagnosis of asthma, 348 were identified as having SUA. A nested sample of 151 patients revealed that 50% were managed by primary care physicians (PCP) and specialists, 43% by PCPs only, and 4% by specialists only. The total costs of the claims were $10.8 million over 5 years ($2.2 million per year), with 60% generated from patients seeing PCPs and specialists, 27% from PCPs only, and 15% from specialists only. During the pandemic, total average costs decreased for all care groups (34% PCP-only patients and 45% for both specialist-only and PCP and specialist patients). Inpatient and outpatient costs also decreased and were lowest for patients who saw specialists and highest for patients who saw PCPs and specialists. In contrast, prescription costs increased during the pandemic. Biologic use was steadily increasing until a twofold decrease was observed during the pandemic. Thirteen patients were on biologics: two were managed by PCPs, four by specialists, and seven by both. <b>Conclusion:</b> Inpatient and outpatient costs decreased during the COVID-19 pandemic, but prescription costs increased. Biologic use was increasing among patients with SUA before the pandemic but then drastically decreased and remained lower during the observational interval.</p>","PeriodicalId":7646,"journal":{"name":"Allergy and asthma proceedings","volume":"44 5","pages":"340-344"},"PeriodicalIF":2.6000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476494/pdf/zsn340.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Allergy and asthma proceedings","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2500/aap.2023.44.230045","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 1

Abstract

Background: Patients with severe uncontrolled asthma (SUA) overwhelmingly contribute to the economic burden of asthma and may require biologic therapy. However, the impact of the CoronaVirus Disease of 2019 (COVID-19) on asthma costs and biologic use has yet to be evaluated. Objective: The objective was to test the hypothesis that SUA costs and biologic use decreased during the pandemic. Methods: We analyzed medical costs and biologic use in patients with SUV from January 2017 to December 2021, by using claims data from a large managed care organization and electronic health record data from Robert Wood Johnson Barnabas Health, according to provider specialty. Results: Of the 3817 managed care organization enrollees within Robert Wood Johnson Barnabas Health with a primary diagnosis of asthma, 348 were identified as having SUA. A nested sample of 151 patients revealed that 50% were managed by primary care physicians (PCP) and specialists, 43% by PCPs only, and 4% by specialists only. The total costs of the claims were $10.8 million over 5 years ($2.2 million per year), with 60% generated from patients seeing PCPs and specialists, 27% from PCPs only, and 15% from specialists only. During the pandemic, total average costs decreased for all care groups (34% PCP-only patients and 45% for both specialist-only and PCP and specialist patients). Inpatient and outpatient costs also decreased and were lowest for patients who saw specialists and highest for patients who saw PCPs and specialists. In contrast, prescription costs increased during the pandemic. Biologic use was steadily increasing until a twofold decrease was observed during the pandemic. Thirteen patients were on biologics: two were managed by PCPs, four by specialists, and seven by both. Conclusion: Inpatient and outpatient costs decreased during the COVID-19 pandemic, but prescription costs increased. Biologic use was increasing among patients with SUA before the pandemic but then drastically decreased and remained lower during the observational interval.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
COVID-19对严重未控制哮喘费用和生物制剂使用的影响。
背景:严重未控制哮喘(SUA)患者极大地增加了哮喘的经济负担,可能需要生物治疗。然而,2019年冠状病毒病(COVID-19)对哮喘成本和生物制剂使用的影响尚未得到评估。目的:目的是验证SUA成本和生物制剂使用在大流行期间下降的假设。方法:根据供应商专业,我们使用大型管理医疗机构的索赔数据和Robert Wood Johnson Barnabas health的电子健康记录数据,分析了2017年1月至2021年12月SUV患者的医疗费用和生物使用情况。结果:在Robert Wood Johnson Barnabas Health的3817名初步诊断为哮喘的管理保健组织入选者中,348人被确定为SUA。151例患者的嵌套样本显示,50%的患者由初级保健医生(PCP)和专家管理,43%的患者仅由初级保健医生管理,4%的患者仅由专家管理。索赔的总费用在5年内为1080万美元(每年220万美元),其中60%来自于就诊于pcp和专科医生的患者,27%来自于pcp, 15%来自于专科医生。在大流行期间,所有护理组的总平均费用下降(仅PCP患者下降34%,仅专科患者和PCP +专科患者均下降45%)。住院和门诊费用也有所下降,看专科医生的患者住院和门诊费用最低,而看pcp和专科医生的患者住院和门诊费用最高。相反,在大流行期间,处方费用增加了。生物制剂的使用一直在稳步增加,直到大流行期间减少了两倍。13名患者使用生物制剂:2名由pcp管理,4名由专家管理,7名由两者管理。结论:2019冠状病毒病大流行期间住院和门诊费用下降,但处方费用增加。在大流行之前,SUA患者的生物制剂使用量在增加,但随后急剧减少,并在观察期间保持较低水平。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
5.70
自引率
35.70%
发文量
106
审稿时长
6-12 weeks
期刊介绍: Allergy & Asthma Proceedings is a peer reviewed publication dedicated to distributing timely scientific research regarding advancements in the knowledge and practice of allergy, asthma and immunology. Its primary readership consists of allergists and pulmonologists. The goal of the Proceedings is to publish articles with a predominantly clinical focus which directly impact quality of care for patients with allergic disease and asthma. Featured topics include asthma, rhinitis, sinusitis, food allergies, allergic skin diseases, diagnostic techniques, allergens, and treatment modalities. Published material includes peer-reviewed original research, clinical trials and review articles.
期刊最新文献
Real-world surveillance of standardized quality (SQ) house dust mite sublingual immunotherapy tablets for 3 years in Japan. A case of a rash after tetanus-diphtheria-pertussis and meningococcal vaccination. Eating increases disease activity in pediatric patients with symptomatic dermographism. A systematic review and meta-analysis exploring the bidirectional association between asthma and gastroesophageal reflux disease in children. Abstracts presented at the Eastern Allergy Conference May 30-June 2, 2024, Palm Beach, Florida.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1